新西兰帕金森病进展计划
Michael R MacAskill1,2, Toni L Pitcher1,2, Tracy R Melzer1,2,3
1New Zealand Brain Research Institute, Christchurch, New Zealand.
Journal of the Royal Society of New Zealand
|October 23, 2024
概括
新西兰帕金森病进展计划 (NZP3) 已经研究了帕金森病的认知障碍14年. 它确定了生物标志物,并确定了帕金森病患者轻度认知障碍 (MCI) 的标准.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
背景情况:
- 新西兰帕金森病进展计划 (NZP3) 已经运行了14年.
- 它涉及354名帕金森病患者和89名健康对照.
- 研究重点是认知障碍及其在帕金森病的早期检测.
研究的目的:
- 在帕金森病中表征认知障碍.
- 为了确定生物标志物来预测未来的认知衰退.
- 建立对帕金森症轻度认知障碍 (MCI) 的标准化标准.
主要方法:
- 纵向研究设计超过14年.
- 参与者招募患有帕金森病的个人和健康的对照.
- 使用脑成像 (MRI,PET),遗传分析,液体生物标志物,眼动,语音分析和定量脑电图 (EEG).
主要成果:
- 对了解帕金森病中轻度认知障碍 (MCI) 的重要贡献.
- 为MCI制定和验证标准化标准.
- 大脑病理 (通过MRI/PET) 和认知能力下降之间确立的关联.
结论:
- 该NZP3计划已经推进了对帕金森病认知障碍的理解和诊断.
- 它是各种研究的平台,包括流行病学和护理人员负担.
- 该计划培养了一个熟练的研究社区,并产生了许多出版物和论文.
相关概念视频
01:15Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
01:24Parkinson's Disease: Treatment
227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227